Chasing High Returns Despite Risks? Three "Problematic" Bio Stocks Land Among Top 15 Ga...
[Yu Jin-hee, Edaily Reporter] As the domestic stock market enters a correction phase, loose liquidity is flowing back into the pharmaceutical and bio sectors.
Investors are returning even to companies previously labeled as "problematic" due to past controversies, regulatory uncertainties, and exaggerated marketing claims.
According to KG Zeroin MP DOCTOR on July 20, Lemon Healthcare, Samchungdang Pharm, and ROKIT Healthcare made the list of the top 15 gainers in the domestic market.
뉴스픽의 주요 문장 추출 기술을 사용하여 “이데일리” 기사 내용을 3줄로 요약한 결과입니다. 일부 누락된 내용이 있어 전반적인 이해를 위해서는 본문 전체 읽기를 권장합니다.
